RIX CORPORATION (7525) investor relations material

Executive summary

• Net sales rose 10.2% year-over-year to ¥13,597 million for Q1 FY2026, with operating profit up 36.9% and ordinary profit up 33.7%.

• Profit attributable to owners of parent increased 26.6% year-over-year to ¥636 million.

• Comprehensive income more than doubled year-over-year, reaching ¥927 million.

• Double-digit growth in sales and profit measures year-over-year, recovering from a prior decline.

• A new Food, Medicine (Pharmaceuticals), & Cosmetics segment was established to enhance efficiency and sales expansion.

Financial highlights

• Gross profit increased to ¥3,716 million from ¥3,168 million year-over-year, up 17.3%.

• Basic earnings per share rose to ¥78.56 from ¥62.09 year-over-year.

• Equity ratio improved to 62.9% from 60.4% at the previous fiscal year-end.

• Net assets increased to ¥29,349 million, up 0.6% from March 31, 2026.

• Total assets decreased 3.4% to ¥45,870 million, mainly due to lower trade receivables and cash.

Outlook and guidance

• FY2026 full-year forecast: Net sales ¥58.0 billion, operating profit ¥4.22 billion, ordinary profit ¥4.36 billion—all expected to reach record highs.

• Double-digit profit growth anticipated, led by Electronics & Semiconductor and Machine Tools segments.

• Profit attributable to owners of parent forecast to decrease due to absence of prior year extraordinary gain; projected at ¥3,000 million, down 5.7% year-over-year.

• Progress toward full-year forecast as of Q1: Net sales 23.4%, operating profit 20.7%.

• Dividend forecast for FY2027 is ¥162 per share, up from ¥157 in FY2026.